GSK’s Cancer Drug Jemperli Receives Priority Review from FDA

The U.S. Food and Drug Administration (FDA) has granted priority review to GSK’s cancer drug Jemperli following pivotal trial results. These trials demonstrated that a significant number of patients showed no detectable signs of rectal tumors for at least one year. This development indicates a potential shift in treatment for certain rectal cancers. If the drug gains approval, some patients may avoid chemotherapy, radiation, and surgery—changing the standard care for a disease traditionally treated with invasive methods.

FDA and International Review

The FDA’s decision deadline is set for February 2027. However, the application qualifies for accelerated consideration through the National Priority Voucher program, potentially allowing for an earlier ruling. The submission also undergoes review under Project Orbis, which provides coordinated international approvals.

AZUR-1 Trial Results

The AZUR-1 trial forms the basis of the FDA’s review. This global phase II trial evaluates Jemperli as a standalone treatment for untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The study achieved its primary endpoint, showing clinical complete responses lasting at least 12 months.

“AZUR-1 met its primary objective by demonstrating meaningful and sustained clinical complete responses for 12 months, meaning no detectable signs of cancer for at least one year,” said Hesham Abdullah, GSK’s senior vice president and global head of oncology R&D, to Newsweek.

154 patients participated in the trial, each receiving nine cycles of Jemperli over six months. Interim safety findings aligned with the drug’s established profile.

Shift in Treatment Strategy

Traditional treatment for this rectal cancer subtype typically involves chemotherapy, radiation, and surgery. Although effective for many, such treatments often lead to lasting complications.

“Traditional stage II and III dMMR/MSI-H treatments have been chemotherapy plus radiation followed by surgery,” Abdullah explained. Despite curative aims, these treatments often result in long-term negative impacts, with nearly one-third of patients dying from cancer spread.

Jemperli might become the first approved immunotherapy aiding some patients to bypass or delay chemotherapy, radiation, and surgery.

Quality-of-Life Considerations

Avoiding surgery with its irreversible consequences is crucial in the AZUR-1 findings, Abdullah noted. Current treatments have steep personal costs, emphasizing the long-term burdens patients face after chemoradiation and surgery.

Abdullah highlighted permanent reliance on a colostomy bag, often linked to physiological dysfunction, psychological distress, social stigma, and additional complications. Fertility issues, lost during chemo-radiation, and other debilitating effects also severely impact day-to-day life.

If Jemperli becomes a first-line option, these outcomes could be avoided for select patients.

Immunotherapy Response Insights

The AZUR-1 results build on Memorial Sloan Kettering Cancer Center’s earlier work, which showed PD-1 blockade can produce complete responses without chemoradiation.

“dMMR/MSI-H tumors often carry many genetic changes, making them more visible to the immune system,” Abdullah stated. Thus, these tumors generally already have immune cells attempting attacks.

“Anti-PD-1 immunotherapies like Jemperli lift the ‘brakes’ on those immune cells, enhancing their attack against cancer. Identifying dMMR/MSI-H through biomarker testing is crucial, though not every patient will respond,” he added.

Regulatory Timeline

While the FDA has set a February 2027 PDUFA date, the National Priority Voucher program may expedite this process. GSK is seeking approval through Project Orbis for simultaneous international regulator reviews.

The priority review highlights the necessity of new options for patients with scarce alternatives.

If approved, Jemperli would be the first immunotherapy permitting delay or elimination of chemotherapy, radiation, and surgery for some patients. Earlier biomarker testing may become essential in diagnostics, with treatment pathways shifting towards immunotherapy-first strategies.

Impact on GSK Oncology

GSK’s oncology portfolio has expanded significantly, with Jemperli central to its immuno-oncology strategy. The company’s share value has risen 9.7% year-to-date, showcasing investor confidence in its pipeline.

Abdullah referred to the AZUR-1 milestone as vital for delivering scientific innovation to patients, noting GSK’s advancement in Phase 3 trials targeting gaps in gastrointestinal cancer care.

Further interim AZUR-1 results will be presented later this year, with full data set to inform global regulatory submissions.